<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240304061169N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-22</date_registration>
      <primary_sponsor>Khomein University of Medical Sciences</primary_sponsor>
      <public_title>Examining the effect of cinnamol and mint mouthwash on oral mucositis</public_title>
      <acronym></acronym>
      <scientific_title>Examining the effect of cinnamol and mint mouthwash on oral mucositis in chemotherapy patients: a clinical trial investigation.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76795</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, participants will be randomized into three groups for treatment: a control group receiving routine mouthwash, a first intervention group receiving mint mouthwash, and a second intervention group receiving cinnamol mouthwash. The randomization will be conducted using a 6-block method. Six cards are selected. The letter A is written on two cards, the letter B is written on the other two cards, and the letter C is written on the remaining two cards. To conceal the cards, they are placed inside the envelope and turned over several times to obscure their order. When each participant enters, a card is selected for them, and the selected card is discarded. This process is repeated for the next five patients until six people are identified. Then, in the same manner, randomization will be conducted for other groups of 6 people to achieve the desired sample size. Write down the person associated with each block so that the final analysis of the information can be conducted, Blinding description: In this research, which is double-blind, the research samples and the researcher conducting the intervention in this study will be blinded. It has been tried to observe the similarity of the intervention in the groups as much as possible.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral mucositis.</hc_freetext>
      <i_freetext>Intervention 1: In the mint group (provided by Barij Essan pharmaceutical company), participants are instructed to utilize mint essence mouthwash, which can be obtained from pharmacies, for a duration of 14 days. The mouthwash should be used three times a day following teeth brushing sessions scheduled in the morning, noon, and night. The recommended method involves diluting 10 drops of peppermint essential oil in 30 cc of water, gargling the solution for one minute, and refraining from consuming any food for an hour thereafter. It is important to note that participants should continue with their regular treatment regimen as prescribed by their healthcare provider, with the exception of using any other topical mouthwash. Group B participants are advised to follow the same protocol, receiving daily mouthwash until the completion of the 14-day period. Intervention 2: Intervention group: In the Cinnamol mouthwash group(provided by Gol Daro pharmaceutical company), participants are instructed to use the mouthwash three times daily following tooth brushing (in the morning, at noon, and at night) for a duration of 14 days. Specifically, individuals are advised to dilute 20-25 drops of the Cinnamol solution in 30 cc of water, gargle with the mixture for one minute, and refrain from eating for one hour thereafter. During this period, participants are to continue with their regular treatment regimen as prescribed by their attending physician, with the exception of using any other topical mouthwash. Intervention 3: In the control group, in addition to the routine treatment, a placebo is also gargled three times a day, in the morning, for 1 minute (receive mouthwash daily until the 14th day) (provided by Barij Essan pharmaceutical company),. After using mouthwash, patients do not consume food or liquids for 1 hour (group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehran Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi street, Khomein</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3881743364</zip>
        <telephone>+98 86 4622 1534</telephone>
        <email>mehranakbari1373@yahoo.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehran Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadi street, Khomein</address>
        <city>Khomein</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3881743364</zip>
        <telephone>+98 86 4622 1534</telephone>
        <email>mehranakbari1373@yahoo.com</email>
        <affiliation>Khomein University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Written consent from participants
Written consent from participantsFull consciousness
Admitted to the oncology department of Khansari Hospital
Similar treatment protocol
age is age 18 maximum age is maximum years. years
Having oral mucositis (minimum score of 1)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of consent to continue participating in the research
Allergy to or oral or solution
The patient's death
The history of using mint and cinnamol mouthwashes
Continuous use of painkillers and drugs
Suffering from gum and tooth diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K13</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other diseases of lip and oral mucosa</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the mint group (provided by Barij Essan pharmaceutical company), participants are instructed to utilize mint essence mouthwash, which can be obtained from pharmacies, for a duration of 14 days. The mouthwash should be used three times a day following teeth brushing sessions scheduled in the morning, noon, and night. The recommended method involves diluting 10 drops of peppermint essential oil in 30 cc of water, gargling the solution for one minute, and refraining from consuming any food for an hour thereafter. It is important to note that participants should continue with their regular treatment regimen as prescribed by their healthcare provider, with the exception of using any other topical mouthwash. Group B participants are advised to follow the same protocol, receiving daily mouthwash until the completion of the 14-day period.</i_keyword>
      <i_keyword>Intervention group: In the Cinnamol mouthwash group(provided by Gol Daro pharmaceutical company), participants are instructed to use the mouthwash three times daily following tooth brushing (in the morning, at noon, and at night) for a duration of 14 days. Specifically, individuals are advised to dilute 20-25 drops of the Cinnamol solution in 30 cc of water, gargle with the mixture for one minute, and refrain from eating for one hour thereafter. During this period, participants are to continue with their regular treatment regimen as prescribed by their attending physician, with the exception of using any other topical mouthwash.</i_keyword>
      <i_keyword>In the control group, in addition to the routine treatment, a placebo is also gargled three times a day, in the morning, for 1 minute (receive mouthwash daily until the 14th day) (provided by Barij Essan pharmaceutical company),. After using mouthwash, patients do not consume food or liquids for 1 hour (group</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Oral mucositis. Timepoint: on the first, seventh and fourteenth days. Method of measurement: Scoring of patients' oral mucositis using the WHO scoring system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khomein University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-06-19</approval_date>
        <contact_name>Khomein University of Medical Sciences</contact_name>
        <contact_address>Azadi street, Khomein Khomein Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
